Patient | Age (years) | Sex | Antecedent infection | Sampling interval (days) | Nadir disability | 1-year disability | Neuro-physiology | Anti-ganglioside antibodies | Antibodies to ECD2-PMP22 (ELISA) | Antibodies to ECD-P0 (ELISA) | |
IL-10 response to PMP22 I | 4, 8, 10, 11, | 45.4 | 9 M | 2 nil | 11.2 (11.3) | 3.8 (1.2) | 1.6 (1.8) | 5 AIDP | 1 IgM GM1 | 1 IgM | 0 |
16, 19, 27, | (20.8) | 2 F | 2 flu | 1 axonal | 3 weak IgM GM1 | 1 IgG | |||||
28, 31, 36, | 3 urti | 3 equivocal | 1 IgG + IgM GM1 | ||||||||
37 | 1 diarr | 2 normal | 6 negative | ||||||||
3 vom | |||||||||||
No IL-10 response to PMP22 I | 5, 6, 7, 9, | 55.6 | 8 M | 4 nil | 17.2 (16.4) | 3.9 (0.8) | 1.5 (1.1) | 5 AIDP | 2 IgM GM1 | 1 IgM + IgG | 1 IgG |
15, 17, 18, | (18.8) | 5 F | 1 flu, vac | 5 equivocal | 1 weak IgM GM1 | 1 IgG | 1 IgM | ||||
22, 23, 24, | 1 herpes, flu | 3 normal | 1 IgG + IgM GM1 | ||||||||
30, 33, 34 | 1 urti | 1 IgM GM1 + IgG GQ1b | |||||||||
3 diarr | 8 negative | ||||||||||
3 urti + diarr | |||||||||||
IL-10 response to P0 II | 4, 8, 16, 24, | 42.1 | 10 M | 3 nil | 15.5 (15.0) | 3.5 (1.2) | 1.0 (1.1) | 5 AIDP | 2 weak IgM GM1 | 1 IgG | 1 IgG |
27, 28, 30, | (18.8) | 1 F | 2 flu | 1 axonal | 1 IgG + IgM GM1 | ||||||
33, 34, 37 | 3 diarr | 2 equivocal | 8 negative | ||||||||
3 vom | 3 normal | ||||||||||
No IL-10 response to P0 II | 5, 6, 7, 9, | 58.4 | 7 M | 3 nil | 13.5 (14.3) | 4.2 (0.6) | 2.0 (1.5) | 5 AIDP | 3 IgM GM1 | 1 IgM | 1 IgM |
10, 11, 15, | (18.4) | 6 F | 1 flu, vac | 6 equivocal | 2 weak IgM GM1 | 1 IgM + IgG | |||||
17, 18, 19, | 1 herpes, flu | 2 normal | 1 IgG + IgM GM1 | 1 IgG | |||||||
22, 23, 36 | 4 urti | 1 IgM GM1 + IgG GQ1b | |||||||||
1 diarr | 6 negative | ||||||||||
3 urti + diarr |
diarr, diarrhoea; urti, upper respiratory tract infection; flu, flu-like symptoms; vom, vomiting; flu vac, influenza vaccination; herpes, genital herpes; nil, no infection history; sampling interval, interval between onset of neurological symptoms and sampling (days); disability, GBS disability scale score at the nadir of disease and after 1 year; neurophysiology, neurophysiological classification; AIDP, acute inflammatory demyelinating polyradiculoneuropathy; na, not available; –, negative; +, positive; ECD2-PMP22, second extracellular domain of PMP22; ECD-P0, extracellular domain of P0.